SynthesisJournal of translational medicine2021
The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis.
Synthesis in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Kidney injury molecule 1 in the early detection of acute kidney injury-a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Muscle ultrasound to diagnose sarcopenia in chronic kidney disease: a systematic review and bayesian bivariate meta-analysis.BMC nephrology · 2024Pooled it
- The value of urinary interleukin-18 in predicting acute kidney injury: a systematic review and meta-analysis.Renal failure · 2022Pooled it
- The neutrophil-to-lymphocyte ratio as a predictive marker for acute kidney injury in hospitalized sepsis patients: a prospective cohort study.BMC nephrology · 2026Article
- Transition from acute kidney injury to chronic kidney disease: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Integrating metabolomics and machine learning with in silico analysis to identify early biomarkers and molecular interactions in sepsis-associated acute kidney injury.Scientific reports · 2026Article
- RPS3 Aggravates Sepsis-Induced Acute Kidney Injury Through Activating NF-kappaB Mediated Renal Inflammatory Responses.Physiological research · 2026Article
- Cardiac surgery-associated acute kidney injury.BJA education · 2026Review
- L-Carnitine, a new biomarker screened based on untargeted metabolomics, predict cardiac surgery-associated acute kidney injury: a prospective cohort study.BMC nephrology · 2026Article
- Acute Kidney Injury Biomarkers in Perioperative Care: A Scoping Review of Clinical Implementation.Diagnostics (Basel, Switzerland) · 2025Review
- Urinary KIM-1 for Early Detection of Acute Kidney Injury in Neonates: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Review
- The Kidney in the Shadow of Cirrhosis: A Critical Review of Renal Failure.Biomedicines · 2025Review
- UNI-494 treatment improves measures of renal dysfunction and cardiac pathology in male rats receiving L-NAME and angiotensin II.Physiological reports · 2025Article
- Urinary Vitamin D Binding Protein and Kidney Injury Molecule-1 Are Potent Predictors of Acute Kidney Injury After Left Ventricular Assist Device Implantation.Biomedicines · 2025Article
- Discovery of a resistant cohort to acute kidney injury: insights from patients with septic shock.Critical care (London, England) · 2025Article
- Authors reply in response to a letter on "impact of aminoglycosides on survival rate and renal outcomes in patients with urosepsis: a multicenter retrospective study".Annals of intensive care · 2025Article
- Kidneys on the Frontline: Nephrologists Tackling the Wilds of Acute Kidney Injury in Trauma Patients-From Pathophysiology to Early Biomarkers.Diagnostics (Basel, Switzerland) · 2025Review
- Blood Retention and Kidney Clearance of Renal-Clearable Gold Nanoparticles Strongly Correlate with Renal Injury Biomarkers.Angewandte Chemie (International ed. in English) · 2025Article
- Blood Biomarkers to Identify Renal Angiomyolipomas in People With Tuberous Sclerosis Complex.Neurology. Genetics · 2025Article
- Preventing acute kidney injury and its longer-term impact in the critically ill.Intensive care medicine · 2025Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of the study was to systematically review relevant studies to evaluate the diagnostic value of urinary kidney injury molecule 1 (uKIM-1) for acute kidney injury (AKI) in adults.
methodWe searched PubMed and Embase for literature published up to November 1st, 2019 and used the Quality Assessment Tool for Diagnosis Accuracy Studies (QUADAS-2) to assess the quality. Then, we extracted useful information from each eligible study and pooled sensitivity, specificity, and area under the curve (AUC) values.
resultsA total of 14 studies with 3300 patients were included. The estimated sensitivity of urinary KIM-1 (uKIM-1) in the diagnosis of AKI was 0.74 (95% CrI 0.62-0.84), and the specificity was 0.84 (95% CrI, 0.76-0.90). The pooled diagnostic odds ratio (DOR) was 15.22 (95% CrI, 6.74-42.20), the RD was 0.55 (95% CrI 0.43-0.70), and the AUC of uKIM-1 in diagnosing AKI was 0.62 (95% CrI 0.41-0.76). The results of the subgroup analysis showed the influence of different factors.
conclusionUrinary KIM-1 is a good predictor for AKI in adult patients with relatively high sensitivity and specificity. However, further research and clinical trials are still needed to confirm whether and how uKIM-1 can be commonly used in clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.